• Je něco špatně v tomto záznamu ?

Continuous direct compression of a commercially batch-manufactured tablet formulation with two different processing lines

J. Lyytikäinen, P. Stasiak, T. Kubelka, I. Bogaerts, A. Wanek, B. Stynen, J. Holman, J. Ketolainen, T. Ervasti, O. Korhonen

. 2024 ; 199 (-) : 114278. [pub] 20240405

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013707

The transfer from batch-based to continuous tablet manufacturing increases the quality and efficiency of processes. Nonetheless, as in the development of a batch process, the continuous process design requires optimization studies to ensure a robust process. In this study, processing of a commercially batch-manufactured tablet product was tested with two continuous direct compression lines while keeping the original formulation composition and tablet quality requirements. Tableting runs were conducted with different values of process parameters. Changes in parameter settings were found to cause differences in tablet properties. Most of these quality properties could be controlled and maintained within the set limits effortlessly already at this stage of studies. However, the API content and content uniformity seemed to require more investigation. The observed content uniformity challenges were traced to individual tablets with a high amount of API. This was suspected to be caused by API micro-agglomerates since tablet weight variability did not explain the issue. This could be solved by adding a mill between two blenders in the process line. Overall, this case study produced promising results with both tested manufacturing lines since many tablet properties complied with the test result limits without optimization of process parameter settings.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013707
003      
CZ-PrNML
005      
20240905133351.0
007      
ta
008      
240725e20240405ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejpb.2024.114278 $2 doi
035    __
$a (PubMed)38583787
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Lyytikäinen, Jenna $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: jenna.lyytikainen@uef.fi
245    10
$a Continuous direct compression of a commercially batch-manufactured tablet formulation with two different processing lines / $c J. Lyytikäinen, P. Stasiak, T. Kubelka, I. Bogaerts, A. Wanek, B. Stynen, J. Holman, J. Ketolainen, T. Ervasti, O. Korhonen
520    9_
$a The transfer from batch-based to continuous tablet manufacturing increases the quality and efficiency of processes. Nonetheless, as in the development of a batch process, the continuous process design requires optimization studies to ensure a robust process. In this study, processing of a commercially batch-manufactured tablet product was tested with two continuous direct compression lines while keeping the original formulation composition and tablet quality requirements. Tableting runs were conducted with different values of process parameters. Changes in parameter settings were found to cause differences in tablet properties. Most of these quality properties could be controlled and maintained within the set limits effortlessly already at this stage of studies. However, the API content and content uniformity seemed to require more investigation. The observed content uniformity challenges were traced to individual tablets with a high amount of API. This was suspected to be caused by API micro-agglomerates since tablet weight variability did not explain the issue. This could be solved by adding a mill between two blenders in the process line. Overall, this case study produced promising results with both tested manufacturing lines since many tablet properties complied with the test result limits without optimization of process parameter settings.
650    12
$a tablety $7 D013607
650    12
$a příprava léků $x metody $7 D004339
650    12
$a farmaceutická chemie $x metody $7 D002626
650    12
$a pomocné látky $x chemie $7 D005079
650    _2
$a farmaceutická technologie $x metody $7 D013678
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stasiak, Pawel $u Zentiva, Prague, Czech Republic. Electronic address: pawel.stasiak@zentiva.com
700    1_
$a Kubelka, Tomáš $u Zentiva, Prague, Czech Republic. Electronic address: Tomas.Kubelka@zentiva.com
700    1_
$a Bogaerts, Ivan $u GEA Process Engineering, Wommelgem, Belgium. Electronic address: Ivan.Bogaerts@gea.com
700    1_
$a Wanek, Adam $u Zentiva, Prague, Czech Republic; UCT Prague, Prague, Czech Republic. Electronic address: adam.wanek@zentiva.com
700    1_
$a Stynen, Bart $u GEA Process Engineering, Wommelgem, Belgium. Electronic address: Bart.Stynen@gea.com
700    1_
$a Holman, James $u GEA Process Engineering, Wommelgem, Belgium. Electronic address: James.Holman@gea.com
700    1_
$a Ketolainen, Jarkko $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: jarkko.ketolainen@uef.fi
700    1_
$a Ervasti, Tuomas $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: tuomas.ervasti@uef.fi
700    1_
$a Korhonen, Ossi $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: ossi.korhonen@uef.fi
773    0_
$w MED00001640 $t European journal of pharmaceutics and biopharmaceutics $x 1873-3441 $g Roč. 199 (20240405), s. 114278
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38583787 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133345 $b ABA008
999    __
$a ok $b bmc $g 2143480 $s 1225573
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 199 $c - $d 114278 $e 20240405 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...